At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users
In Brief
A Phase 2 clinical trial evaluating Ketamine 0.41 mg/kg, Ketamine 0.71 mg/kg, and 1 other intervention for Cocaine Dependence. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human subjects have been unsuccessful to date. The purpose of this investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting cocaine in cocaine dependent participants, 24-hours post-infusion.
Study Details
Timeline
Interventions
52 minute iv infusion of ketamine 0.41 mg/kg
52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
52 minute infusion of lorazepam 2 mg. This serves as an active control.